Regarding the correlation between LRG1 level and treatment outcomes in patients with autoimmune diseases, only one previous study reported this topic, which revealed that LRG1 gene expression was dysregulated in canakinumab responders compared with canakinumab non-responders among systemic juvenile idiopathic arthritis patients [34]. The gene discussed is LRG1; the disease is juvenile idiopathic arthritis.